Accepted author manuscript, 399 KB, PDF document
Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Final published version
Licence: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
T2 - A longitudinal analysis of Portuguese NHS hospitals, 2015–2021
AU - Perelman, Julian
AU - Duarte-Ramos, Filipa
AU - Gouveia, António Melo
AU - Pinheiro, Luis
AU - Ramos, Francisco
AU - Vogler, Sabine
AU - Mateus, Céu
PY - 2023/1/31
Y1 - 2023/1/31
N2 - BackgroundThere is limited evidence on within-country discrepancies in biosimilar uptake. This study analyzes differences in timing and diffusion of biosimilar uptake across Portuguese NHS hospitals and explores possible determinants.Research design and methodsWe analyzed publicly accessible consumption data of originator biologic and biosimilar drugs for adalimumab, etanercept, infliximab, rituximab, and trastuzumab, by hospital and month for the years 2015–2021 (N = 9,467). We modeled the time to biosimilar adoption using survival regression models and the share of biosimilar consumption using generalized estimated equations with random hospital effects.ResultsAcademic hospitals were characterized by a quicker uptake of adalimumab and infliximab biosimilars but lower shares for other drugs. A higher total consumption of biologics was related to a lower share of biosimilar uptake. A stronger participation in randomized controlled trials was linked to higher biosimilar shares and quicker uptake, except for rituximab. If all NHS hospitals had biosimilar shares equal to the highest ones, potential annual savings could reach 13.9 million euros.ConclusionThe findings suggest a need for capacity-building on biosimilar prescribing, including for doctors of academic hospitals and those working in settings where high biosimilar use would be expected.
AB - BackgroundThere is limited evidence on within-country discrepancies in biosimilar uptake. This study analyzes differences in timing and diffusion of biosimilar uptake across Portuguese NHS hospitals and explores possible determinants.Research design and methodsWe analyzed publicly accessible consumption data of originator biologic and biosimilar drugs for adalimumab, etanercept, infliximab, rituximab, and trastuzumab, by hospital and month for the years 2015–2021 (N = 9,467). We modeled the time to biosimilar adoption using survival regression models and the share of biosimilar consumption using generalized estimated equations with random hospital effects.ResultsAcademic hospitals were characterized by a quicker uptake of adalimumab and infliximab biosimilars but lower shares for other drugs. A higher total consumption of biologics was related to a lower share of biosimilar uptake. A stronger participation in randomized controlled trials was linked to higher biosimilar shares and quicker uptake, except for rituximab. If all NHS hospitals had biosimilar shares equal to the highest ones, potential annual savings could reach 13.9 million euros.ConclusionThe findings suggest a need for capacity-building on biosimilar prescribing, including for doctors of academic hospitals and those working in settings where high biosimilar use would be expected.
KW - Biosimilar
KW - uptake
KW - diffusion
KW - intra-country differences
KW - hospital-related determinants
KW - savings
KW - Portugal
U2 - 10.1080/14737167.2023.2146579
DO - 10.1080/14737167.2023.2146579
M3 - Journal article
VL - 23
SP - 99
EP - 109
JO - Expert Review of Pharmacoeconomics & Outcomes Research
JF - Expert Review of Pharmacoeconomics & Outcomes Research
IS - 1
ER -